<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818194</url>
  </required_header>
  <id_info>
    <org_study_id>FKC-012</org_study_id>
    <secondary_id>Health Canada Control # 119562</secondary_id>
    <nct_id>NCT00818194</nct_id>
  </id_info>
  <brief_title>Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers</brief_title>
  <official_title>A Comparison of Effects of Short-term Low Dose Exposure of Advagraf速 and Neoral速 Microemulsion Cyclosporine A on Renal Perfusion and Function in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Canada, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of steady state tacrolimus vs.
      cyclosporine on renal pharmacodynamics in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to evaluate the renal physiological responses of short-term maintenance
      level doses of CNIs in healthy volunteers to determine if daily perturbations in renal
      physiology exist, and if confirmed, whether they differ between CNIs and thus may contribute
      by different mechanisms to the progression of CAN.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Effective Renal Plasma Flow response</measure>
    <time_frame>Baseline and Day 10 of each dosing interval</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Glomerular Filtration Rate response</measure>
    <time_frame>Baseline and Day 10 of each dosing interval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of blood pressure response</measure>
    <time_frame>Baseline and Day 10 of each dosing interval</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A. tacrolimus first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive extended release tacrolimus in first dosing interval then cross over to cyclosporine A for second dosing interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. cyclosporine first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive cyclosporine A in first dosing interval then cross over to extended release tacrolimus for second dosing interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>extended release tacrolimus</intervention_name>
    <description>oral</description>
    <arm_group_label>A. tacrolimus first</arm_group_label>
    <arm_group_label>B. cyclosporine first</arm_group_label>
    <other_name>Advagraf速</other_name>
    <other_name>FK506E</other_name>
    <other_name>MR4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine A microemulsion</intervention_name>
    <description>oral</description>
    <arm_group_label>A. tacrolimus first</arm_group_label>
    <arm_group_label>B. cyclosporine first</arm_group_label>
    <other_name>Neoral速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  caucasian

          -  healthy with no history or current clinical findings of infection or disease of the
             following nature: cerebrovascular, neurologic, cardiovascular, endocrine, pulmonary,
             immunologic, metabolic, hematologic, diabetes mellitus, glucose intolerance, gout

          -  non-smoker and willing to abstain from alcohol consumption during the study

          -  agrees to use appropriate contraception during the study period until 3 months after
             the final study exam.

        Exclusion Criteria:

          -  history of significant alcohol abuse or drug abuse within 1 year prior to the
             screening visit

          -  regular use of alcohol within 6 months prior to the screening visit (more than 14
             units of alcohol per week)

          -  use of soft drugs (marijuana) within 3 months prior to the screening visit or hard
             drugs (cocaine, PCP, crack) within 1 year prior to the screening visit Hepatitis B or
             C, HIV, history of cancer (excluding excised squamous or basal cell carcinoma)

          -  positive tuberculin skin test or prior TB infection

          -  known history of serious head injuries, seizures or any eating disorder

          -  received an investigational drug within 30 days prior to the first study drug
             administration

          -  known hypersensitivity/allergy to tacrolimus, cyclosporine, iothalamate iodine,
             para-aminohippuric acid, antibiotics or antifungals

          -  Body mass index (BMI) &lt;19 or &gt;27

          -  clinically significant history of psychiatric disease or a significant disability that
             prevents understanding or adherence to protocol

          -  renal dysfunction, serum creatinine or urine microalbumin above the normal age and
             gender-adjusted reference range of the local lab

          -  clinically significant abnormal liver function test indicative of impaired hepatic
             function

          -  received medications/herbal preparations that may affect the metabolism of tacrolimus
             or cyclosporine A within 1 month of the first study drug administration

          -  received any other prescription medication within 14 days prior to the first study
             drug administration or any over-the-counter product within 7 days prior to the first
             study drug administration, except for topical products without systemic absorption

          -  current GI condition known to affect GI motility and/or absorption

          -  donation of plasma (500 mL) within 7 days prior to the first study drug administration
             or donation/ loss of whole blood as follows: 50 mL to 499 mL within 30 days or more
             than 499 mL within 56 days prior to the first study drug administration

          -  clinically significant surgery within 4 weeks prior to the first study drug
             administration

          -  administration of steroids by injection within 12 weeks prior to the first study drug
             administration

          -  administration of any live vaccine within 7 days prior to the first study drug
             administration

          -  travel in areas where TB is endemic within 8 weeks prior to the TB skin test performed
             at the screening visit

          -  hemoglobin &lt;140 g/L
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Canada, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 140499 in the JapicCTI-RNo. field</description>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>cyclosporine A</keyword>
  <keyword>renal plasma flow</keyword>
  <keyword>glomerular filtration rate</keyword>
  <keyword>human</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Pharmacodynamics of tacrolimus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

